n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, May 16th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Identillect Technologies Corp. (IDTLF)

We are reporting on Identillect Technologies Corp. (IDTLF) today, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Identillect Technologies Corp. is a foremost provider of SaaS (Software as a Service) email security. The Company’s Delivery Trust™ email security technology platform permits individuals and businesses of all sizes a cost-effective way to create a more secure digital environment and protect against cyber security risks. Identillect Technologies has its corporate office in Irvine, California.

Delivery Trust™ is the industry’s simplest plug and play security solution. It has an extensive range of features. These include state of the art encryption technology, restricting email forwarding and printing, receipt confirmation, limiting time available to view, and retracting sent emails. Delivery Trust™ is available for iPhone®, iPad®, Android, Windows and Mac PC's and Laptops and the web's most popular email platforms.

Recently, Identillect Technologies announced a new service collaboration with the National Association of Professional Agents (NAPA), providing NAPA members access to the Company's set of compliance tools. This includes the Identillect Delivery Trust™ email encryption service. NAPA specializes in building custom company-sponsored E&O and benefit programs tailored to meet the unique requirements of a sponsoring company’s distribution force.

The design of these security solutions is to respond to agents need to successfully ensure or improve their HIPAA compliance. Delivery Trust™ is an email encryption solution. It is being deployed by small businesses and enterprises at a monthly subscription fee.

Last week, Identillect Technologies announced positive growth numbers for April 2017. Continuing the quarter over quarter growth, the Company has seen 18 percent growth in April versus the Q1 2017 monthly average. The growing demand for regulatory compliant email is being seen at a state, federal, as well as industry level.

Mr. Todd Sexton, Chief Executive Officer of Identillect Technologies, stated, "We are seeing such a progressive change in the requirement for secure communication at all regulatory levels, with additional movement around the state regulatory demands. The features and security that our Delivery Trust email security service offers, help businesses and end users to meet these ever-increasing regulations."

Identillect Technologies Corp. (IDTLF), closed Tuesday's trading session at $0.08, up 2.56%, on 17,500 volume with 7 trades. The average volume for the last 60 days is 47,954 and the stock's 52-week low/high is $0.0579/$0.16.

All for One Media Corp. (AFOM)

OTC Markets, MarketWatch, Street Register, Blomberg, InvestorsHub, and Barchart reported on All for One Media Corp. (AFOM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

All for One Media Corp. is a tween marketing company headquartered in Mount Kisco, New York. The estimation is that the tween demographic is responsible for no less than $260 billion annually in direct sales in the United States alone. Called “Generation I” for "Internet," this generation's tweens represent the first demographic to have had only known life with the Internet and social media. Fundamentally, All for One Media is a marketing brand changing the mindset of tweens that bullying is unacceptable.  All for One Media lists on the OTC Markets’ OTCQB.

The Company is currently producing "Crazy For the Boys," scheduled to begin principal photography this summer. All for One Media, through entertainment, is working to deliver a message that will resonate with kids to impact the epidemic of bullying and cyber-bullying. In addition, the Company is working to help individuals who have been affected by bullying to deal with it in a positive and constructive way.

 “Crazy For The Boys” is a full length coming of age musical dramedy. It features Groovy Tuesday music and choreography. This film tells the story of five high school girls from five very different cliques who must work together to run their school’s anti-bullying organization. The film features original pop songs pertaining to peer pressure, unrequited love, as well as teen angst.

The expectation is that “Crazy For The Boys” will generate revenues from several sources. These include domestic and international distribution, video on demand, merchandising, soundtrack, live performances, and other ancillary sources.

All for One Media has initiated the recording of the sixteen songs, which will be included in "Crazy for the Boys", and also included on the Soundtrack for the movie. A number of the songs will be produced by multi-platinum Producer Jeff Coplan. Recording started on May 2, 2017 at legendary studio "The Jungle Room" in Glendale, California.

Last week, All for One Media announced that it reached an agreement with a Savannah, Georgia film studio on financing of “Crazy for the Boys”. The studio has committed to invest $890,000 in equity into the deal. This allows All for One Media to begin pre-production next month. All for One Media and its subsidiary Crazy for the Boys Movie, LLC are scheduled to start two weeks of 'Boot Camp' rehearsals followed immediately by Principal Photography beginning in July 2017.

All for One Media Corp. (AFOM), closed Tuesday's trading session at $0.043, down 20.37%, on 199,894 volume with 21 trades. The average volume for the last 60 days is 195,020 and the stock's 52-week low/high is $0.0338/$0.55.

Tempus Applied Solutions Holdings, Inc. (TMPS)

InvestorsHub and MarketWatch reported on Tempus Applied Solutions Holdings, Inc. (TMPS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Tempus Applied Solutions Holdings, Inc. provides design, engineering, systems integration, and flight operations solutions. These support critical aviation mission requirements for an array of customers. The Company maintains a highly qualified and skilled in-house engineering team that supports aircraft modifications, certification, maintenance, and flight testing. Tempus Applied Solutions, LLC is the wholly-owned subsidiary of Tempus Applied Solutions Holdings, Inc.  Tempus Applied Solutions is based in Williamsburg, Virginia.
 
The Company flies airplanes - fixed wing and rotary, manned or unmanned. It engages in surveillance missions in Africa to flight training in Texas. Also, Tempus designs and modifies aircraft for special missions, certifies them, and provides turnkey lease and service solutions.

The Company operates Gulfstream, Bombardier, Pilatus, and Cessna aircraft. Most of these aircraft have been specially modified by Tempus for DoD-related missions. This includes threat simulation, surveillance, communications relay, and varied test and development programs.

The Company’s Tempus Applied Solutions subsidiary has been awarded FAA (Federal Aviation Administration) approval, in the form of a Supplemental Type Certificate (STC), for Tempus' initial FANS/1-A and ADS-B compliance solution [(Tempus' "Solution AA")]. Tempus' solution has received an "Approved Model List", or AML, STC, which means that it can be applied to any business and commercial aircraft.  FANS and ADS-B compliance will be mandated in most parts of the world by 2020.

Tempus Applied Solutions utilizes a secure facility with hangar and manufacturing space and secure communications at Brunswick Executive Airport. The facility has two parallel 8000’ x 200’ runways and a 4.5-million-square-foot ramp and taxiways - certified for B-747, A-340, as well as C-5 aircraft. The Company’s customers include NASA (National Aeronautics and Space Administration), the United States Department of Defense, Northrop Grumman, L-3 Communications, United States Africa Command, Joint Special Operations Command, and numerous other government agencies, individuals, and corporations.

The Tempus Design & Engineering Center of Excellence has Designated Engineering Representative (DER) authority from the Federal Aviation Administration (FAA) and the European Aviation Safety Agency (EASA). This center’s specialties include major airframe modifications; interior completions projects; design and materials specifications; modeling and rendering using 3D Max Vision; Supplemental Type Certificates (STC); and Layout of Passenger Accommodations (LOPA) Development.

Tempus Applied Solutions Holdings, Inc. (TMPS), closed Tuesday's trading session at $0.0501, down 64.47%, on 61,285 volume with 11 trades. The average volume for the last 60 days is 14,488 and the stock's 52-week low/high is $0.0592/$2.15.

Luvu Brands, Inc. (LUVU)

FeedBlitz, Penny Dreamers, Buzz Stocks, Beacon Equity Research, InvestorSoup, Penny Stocks Finder, SimplyBestPennyStocks, Stock Preacher, Stock Roach, StockHideout, The Stock Psycho, Top Best Pennystocks, Investor News Source, Penny Stocks VIP, and Top Gun reported earlier on Luvu Brands, Inc. (LUVU), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Luvu Brands, Inc. is a manufacturer and marketer of premium consumer brands in the intimacy enhancement, top-of-bed relaxation and fashion beanbags, loungers and sofas categories. The Company’s brand sites include liberator.com, theliberator.co.uk, jaxxliving.com, avanacomfort.com, in addition to other global e-commerce sites. Luvu Brands’ shares trade on the OTC Markets Group’s OTCQB. The Company has its headquarters in Atlanta, Georgia.

Luvu Brands promotes its products around the world in a variety of distribution channels. These channels include mass market web retailers, catalogers, and specialty retail stores.

The Company is headquartered in a 140,000-square foot vertically-integrated manufacturing facility. Luvu designs, manufactures, licenses, and markets a collection of premier consumer lifestyle brands. These include sexual wellness, fashion seating and furniture, and home essentials.

In December 2016, Luvu Brands announced the signing of an exclusive sales and marketing agreement with MysteryVibe Limited. MysteryVibe is an award-winning British pleasure products brand. It designs, develops, and manufactures luxury products in this category. MysteryVibe is based in London, United Kingdom.

Yesterday, Luvu Brands reported financial results for the three and nine months ended March 31, 2017. Operating highlights for the quarter ended March 31, 2017 include
Net Sales decreasing 6 percent to $4.0 million for Q3 of fiscal 2017, versus $4.3 million for the comparable year ago period. Gross Margin grew to 33.5 percent, considerably higher than the 24.1 percent Gross Margin reported for the three months ended March 31, 2016.

Total Gross Profit rose 30 percent to $1.3 million, versus $1.0 million for the comparable year ago period. Net Income rose to $111,000 during the current year Q3 versus a Net Loss of ($159,000) in the prior-year Q3.  EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), as adjusted, grew to $302,000 in Q3, versus $22,000 in Q3 of fiscal 2016.

Mr. Louis Friedman, Luvu Brands’ Chairman and Chief Executive Officer, said, "We are pleased with the improved operating performance of the Company, despite the decrease in sales during the quarter. As we previously announced, we are focusing more on sales of our manufactured products and less on lower margin distributed products.”

Luvu Brands, Inc. (LUVU), closed Tuesday's trading session at $0.075, even for the day. The average volume for the last 60 days is 16,504 and the stock's 52-week low/high is $0.0111/$0.089.

SurePure, Inc. (SURP)

Greenbackers reported previously on SurePure, Inc. (SURP), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

SurePure, Inc. is a worldwide leader in liquid photopurification - the green alternative to pasteurization and chemicals. Utilizing its patented 'Turbulator™' technology, the Company’s systems use UV-C light to purify microbiologically sensitive liquids. The design of SurePure’s technology is to deliver food-grade solutions. Additionally, this technology can be harnessed to improve processing liquids, including water, brines and sugar syrup solutions, and animal blood plasma. SurePure is based in New York, New York.

SurePure’s technology delivers replicable, predictable, germicidal efficacy. The technology provides greater microbiological effectiveness than conventional UV systems. The technology is effective for clear and turbid liquids. The Company’s patented SurePure Turbulator design increases the liquids’ exposure to UV-C. This enables greater efficacy and consistency in purification.

The turbulent flow of the liquid over the lamps ensures a non-fouling, self-cleaning system. Furthermore, the multiple-lamp system guarantees added food-safety peace-of-mind.

In addition, SurePure provides opportunities for the development of innovative and differentiated products with desired consumer benefits, guaranteed food safety, and sound commercial benefits. Its liquid photopurification technology purifies turbid liquids. These include milk, beer, fruit juice, wine, carbonated beverages, and an array of industrial applications.

SurePure’s patented technology utilizes a specific band of ultraviolet light to provide a green alternative to heat and chemicals in the purification of turbid liquids. Pertaining to dairy, SurePure photopurification reduces the microbial load of milk at all levels. Moreover, it deactivates viruses, bacteria, yeasts, and molds.

Recently, SurePure announced that Tamarack Biotics completed a self-affirmed "Generally Recognized as Safe" (GRAS) approval for its TruActive™ NF product. The process adopted by Tamarack Biotics has at its core SurePure's patented 'Turbulator™' technology. Tamarack earlier entered into a right to purchase SurePure units. Tamarack develops dairy products that retain more of the immune active proteins and other thermally sensitive compounds found in raw milk.

Tamarack Biotics employs the SurePure photo purification technology for non-thermal pathogen reduction and low temperature drying technologies, which completely dry milk and milk concentrates into stable powders at temperatures not exceeding a cow's normal body temperature.

SurePure, Inc. (SURP), closed Tuesday's trading session at $0.09, up 5.88%, on 205,511 volume with 13 trades. The average volume for the last 60 days is 43,747 and the stock's 52-week low/high is $0.04/$0.225.

graphic

The QualityStocks
Company Corner

graphic
graphic

CD International Enterprises, Inc. (CDII)

The QualityStocks Daily Newsletter would like to spotlight CD International Enterprises, Inc. (CDII). Today, CD International Enterprises, Inc. closed trading at $0.009, up 11.11%, on 6,474,064 volume with 192 trades. The stock’s average daily volume over the past 60 days is 1,983,356 and its 52-week low/high is $0.0001/$12.00.

CD International Enterprises, Inc. a U.S.-based company that sources industrial commodities and provides business and management corporate consulting services, today announces that it has entered into a wholesale distribution agreement with GWR Distributors, Inc. based in the U.S., GWR Distributors is one of the world's leading suppliers of cannabidiol (CBD)-based products derived from hemp.

CD International Enterprises, Inc. (CDII) is a U.S.-based company operating in two primary business segments: mineral trading and consulting services. Headquartered in Deerfield Beach, Florida, with operations centering on the rapid growth of the Chinese economy, CDII allows prospective investors to participate in the considerable opportunities presented by emerging markets in both the People's Republic of China and the Americas.

CDII Minerals, Inc., a wholly-owned subsidiary of CD International, serves as its commodities trading division. Through CDII Minerals, CDII sources, aggregates and distributes iron ore, manganese ore and scrap metals for clients operating throughout China. The company maintains a strategic position between its North and South American suppliers and its Chinese clients, allowing it to both address a niche market opportunity and facilitate more efficient transactions for its customers.

In addition to its mineral trading services, CDII has found success in offering a comprehensive suite of consulting services related to the unique characteristics of business operations in China. In December 2016, the company announced its entry into a two-year corporate agreement with a China-based subsidiary of Everbright International Construction Engineering Corporation, through which CDII will provide information related to foreign and domestic constructions, project tending offers, government communications and local networks. In January 2017, CDII announced its entry into a similar agreement with Zhangjiajie Shengshi Agricultural Development Company, through which it will provide consulting services related to a number of business developments, including the development of a distribution business centered on cannabidiol extract derived from industrial hemp.

Per the company's website, CDII's greatest strength lies in the quality of its personnel, which includes a culturally diverse group of professionals operating within the United States, as well as in China and emerging markets throughout the Americas. Dr. James Wang has served as CEO and chairman of the CDII board since August 2006. He has also served as CEO and chairman of China Direct Investments since January 2005. Wang brings a wealth of experience in corporate finance in the U.S. capital markets to the CDII management team, and his work in the identification and acquisition of China-based growth companies has played an instrumental role in the execution of CD International's strategic vision for over a decade.

Wang is joined on the CDII management team by Controller Shirley Xu and Vice President of Business Development Katie Zhao. Xu has served as the company's controller since January 2013, assuming a range of responsibilities including internal control, general ledger accounting oversight, and financial reporting for CDII and its subsidiaries. She is also responsible for SEC financial reporting for the company's consulting segment clients.

Katie Zhao has served in her current role with CD International since January 2012. Prior to becoming VP of business development, she served as the company's project manager from 2007 to 2009 and as senior account executive from 2010 to 2011. From these positions, Zhao played a key role in the establishment of CDII's U.S. distribution channels for its Chinese clients, as well as the implementation of a network connecting the company's U.S. and China-based offices. Disclaimer

CD International Enterprises, Inc. Blog

CD International Enterprises, Inc. News:

CD International Enterprises Enters Wholesale Distribution Agreement With Leading Global Supplier of Cannabidiol/Hemp-Derived Products

CD International Enterprises (OTC: CDII) Enters a Full Corporate Offer To Purchase Copper Cathodes Valued at Approximately $330 Million

CD International Enterprises (CDII) Signs a Letter of Intent to Purchase Iron Ore

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $1.06, even with yesterday's close, on 4,780 volume with 12 trades. The stock’s average daily volume over the past 60 days is 73,888 and its 52-week low/high is $0.12/$2.75.

ChineseInvestors.com is projected to reach revenues of $14.8 million by fiscal year 2020, according to a new research report by Consilium Global Research (http://nnw.fm/kKO7e). Per the report, the company did $930,000 in revenue for fiscal 2016 and is projected to grow at a compound annual growth rate (CAGR) of approximately 100% through 2020. The underlying market’s CAGR will expand at an 80% rate, the report said. Consilium sees CIIX as going through a huge transformation this year as it pursues a larger stake in the cannabis market.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

ChineseInvestors.com, Inc. (CIIX) Projected To Reach Revenue of $14.8 Million by FY2020 in Consilium Global Research Report

ChineseInvestors.com, Inc. Appoints Summer Yun as CEO of CBD Biotechnology Co., Ltd., Wholly-owned Foreign Entity

Consilium Global Research Issues Executive Summary on Chinese Investors.com, Inc. (OTCQB: CIIX)

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.37, off by 7.50%, on 141,376 volume with 365 trades. The stock’s average daily volume over the past 60 days is 421,738, and its 52-week low/high is $0.19/$0.80.

India Globalization Capital, Inc. announces that Craig Cheifetz, M.D. has joined the company as an advisor to provide guidance on clinical trials, biotechnology, neuroscience, immunology and microbiology. Dr. Cheifetz is currently Regional Dean at Virginia Commonwealth University Inova Fairfax Campus and is the Medical Director of Inova VIP 360 (Northern Virginia's premier Concierge Medicine Program). Dr. Cheifetz received his M.D. from the State University of New York College at Buffalo and trained in Internal Medicine at Georgetown University. From 2011 to 2013, he served as the National GRMC Chairman.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Appoints Medical Advisor Craig Cheifetz, M.D. to Consult on the Development of Cannabis-Based, Combination Therapies

IGC Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain

IGC Sells Malaysian Hotel Investment Interest, Consolidates Corporate Focus on Development of Cannabis-Based Combination Therapies

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.44, up 12.82%, on 645,964 volume with 340 trades. The stock’s average daily volume over the past 60 days is 1,098,903, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

InMed's Exceptional Management Team Executes Ambitious Plan -- CFN Media

GreenStone Healthcare Corp. (GRST)

The QualityStocks Daily Newsletter would like to spotlight GreenStone Healthcare Corp. (GRST). Today, GreenStone Healthcare Corp. closed trading at $0.0419, up 10.26%, on 15,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 56,868, and its 52-week low/high is $0.015/$0.083.

GreenStone Healthcare Corp. (GRST), through its subsidiaries, offers addiction and mental health rehabilitation treatments for residents, including out-patient counseling, coaching, intervention, psychological assessment, and other related services. The company recently sold its Canadian addiction treatment operations and acquired a U.S. based treatment center in Delray Beach, Florida, a major U.S. center for drug treatment programs located between Palm Beach and Miami. The company sought to expand into the U.S., where it could revolutionize treatment in that country with the skills it acquired in Canada. The company, through a subsidiary, will own and lease their assets in Canada, offering a stable secondary cash flow. Their newly acquired U.S. treatment center will be operated through a Florida limited liability company named Seastone Delray Healthcare LLC.

More than two thirds of families have been touched by a family member's addiction to alcohol, drugs, sex, and/or gambling. The addiction treatment market in the U.S. is estimated at over $35 billion annually, with a greater need than there are facilities. In addition, the GreeneStone approach differentiates itself in a number of ways:

  • Residents are treated holistically, taking into consideration all factors that can feed addiction, rather than the isolated treatment of addiction alone. Upon admission, all residents are fully assessed by professionals of a multidisciplinary team to develop an overall holistic treatment plan. An assembled team of best-in-class experts, including psychiatrists, physicians, nurses, and clinicians, manage and support residents who have co-occurring disorders such as depression, anxiety, and trauma.
  • Support is available both before and after resident treatment. Families can receive intervention support prior to admission, an often critical time for families and patients. Follow-up treatment support is available, to ensure progress and minimize the incidence of relapse. Families and others that are integral to the recovery are encouraged to participate in counseling and education sessions for continued success after in-patient treatment.

In addition to his experience with GreeneStone Healthcare, company president Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. Disclaimer

GreenStone Healthcare Corp. Company Blog

GreenStone Healthcare Corp. News:

GreeneStone Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida

GreeneStone Signs Definitive Agreement to Acquire Seastone of Delray, a Florida Limited Liability Company

GreeneStone Signs LOI to Acquire Aurora Recovery

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Profitable Trader Authority
(CLOW) +84.86%

2.

Stock Beast
(XGTI) +39.31%

3.

Profitable Trader Authority
(CTBO) +28.12%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251